Gaucher disease, the most common lysosomal storage disorder, is a heterogeneous multisystem
condition. Patients with non-neuronopathic (type 1) Gaucher disease may suffer from …

Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal
disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) …

Objective: To compare the efficacy of mannose-terminated glucocerebrosidase prepared
from natural (alglucerase; Ceredase, Genzyme Corp., Cambridge, Massachusetts) and …

OBJECTIVE: To confirm the efficacy and safety of recombinant human α-L-iduronidase (laronidase)
in patients with mucopolysaccharidosis I (MPS I). STUDY DESIGN: This was a …

PURPOSE: Gaucher disease is the first lysosomal storage disorder to be treated with
macrophage-targeted enzyme replacement therapy. Previous studies in relatively small numbers of …

Background The Gaucher Registry, the largest database of patients with Gaucher disease (GD)
worldwide, was initiated to better delineate the progressive nature of the disorder and …

Fabry disease (FD) is an X-linked lysosomal storage disease caused by alpha-galactosidase
A deficiency. The Fabry Registry is a global clinical effort to collect longitudinal data on FD. …

A global, observational disease registry has been established to characterize the course of
disease and track clinical outcomes in patients with Mucopolysaccharidosis Type I (MPS I), a …

Fabry disease is an X-linked metabolic storage disorder due to the deficiency of lysosomal α-galactosidase
A, and the subsequent accumulation of glycosphingolipids, primarily …

OBJECTIVE. Our goal was to evaluate the long-term safety and efficacy of recombinant
human α-l-iduronidase (laronidase) in patients with mucopolysaccharidosis I. PATIENTS AND …